{"title":"在动物模型中，硫化氢对顺铂诱导的实验性肾毒性具有保护作用：一项系统综述和荟萃分析。","authors":"Zhenyuan Han, Tianyu Deng, Dechao Yan, Yutao Jia, Jing Tang, Xiaoyan Wang","doi":"10.7717/peerj.19481","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cisplatin-induced acute kidney injury (cis-AKI) is not rare in oncological patients clinically, but there are limited prevention and treatment methods available. The efficacy of hydrogen sulfide (H<sub>2</sub>S) in mitigating cis-AKI has been studied and determined in animal models.</p><p><strong>Methods: </strong>According to the pre-registered program (PROSPERO: CRD 42023463779), we searched PubMed/Medline, Embase, and Web of Science databases using the keywords: hydrogen sulfide, cisplatin, acute kidney injury, and alternatives. A total of 13 articles met the inclusion criteria were included. Standardized mean difference (SMD) and 95% confidence interval (CI) were calculated and aggregated using random effects meta-analysis.</p><p><strong>Results: </strong>The results showed that H<sub>2</sub>S treatment significantly improved renal function (serum creatinine SMD = -2.96, 95% CI [-3.72 to -2.19], <i>p</i> < 0.00001; blood urea nitrogen SMD = -2.73, 95% CI [-3.68 to -1.78], <i>p</i> < 0.00001), decreased oxidative stress (superoxide dismutase SMD = 2.90, 95% CI [1.36-4.43], <i>p</i> = 0.0002) and inflammation levels (interleukin-1β SMD = -4.41, 95% CI [-5.84 to -2.97], <i>p</i> < 0.00001). However, there was a high degree of heterogeneity between studies (I<sup>2</sup> > 70%). Further subgroup analysis did not show a clear source of the heterogeneity, but various H<sub>2</sub>S donors exhibited positive renal protection in those studies.</p><p><strong>Conclusions: </strong>H<sub>2</sub>S could be a new approach for treating cis-AKI, while the differential efficacies among natural and slow-release H<sub>2</sub>S donors remain to be compared and evaluated further. This meta-analysis may shed light on establishing preclinical and clinical investigation guidelines for treating human cis-AKI with H<sub>2</sub>S donors.</p>","PeriodicalId":19799,"journal":{"name":"PeerJ","volume":"13 ","pages":"e19481"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103845/pdf/","citationCount":"0","resultStr":"{\"title\":\"Hydrogen sulfide protects against cisplatin-induced experimental nephrotoxicity in animal models: a systematic review and meta-analysis.\",\"authors\":\"Zhenyuan Han, Tianyu Deng, Dechao Yan, Yutao Jia, Jing Tang, Xiaoyan Wang\",\"doi\":\"10.7717/peerj.19481\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cisplatin-induced acute kidney injury (cis-AKI) is not rare in oncological patients clinically, but there are limited prevention and treatment methods available. The efficacy of hydrogen sulfide (H<sub>2</sub>S) in mitigating cis-AKI has been studied and determined in animal models.</p><p><strong>Methods: </strong>According to the pre-registered program (PROSPERO: CRD 42023463779), we searched PubMed/Medline, Embase, and Web of Science databases using the keywords: hydrogen sulfide, cisplatin, acute kidney injury, and alternatives. A total of 13 articles met the inclusion criteria were included. Standardized mean difference (SMD) and 95% confidence interval (CI) were calculated and aggregated using random effects meta-analysis.</p><p><strong>Results: </strong>The results showed that H<sub>2</sub>S treatment significantly improved renal function (serum creatinine SMD = -2.96, 95% CI [-3.72 to -2.19], <i>p</i> < 0.00001; blood urea nitrogen SMD = -2.73, 95% CI [-3.68 to -1.78], <i>p</i> < 0.00001), decreased oxidative stress (superoxide dismutase SMD = 2.90, 95% CI [1.36-4.43], <i>p</i> = 0.0002) and inflammation levels (interleukin-1β SMD = -4.41, 95% CI [-5.84 to -2.97], <i>p</i> < 0.00001). However, there was a high degree of heterogeneity between studies (I<sup>2</sup> > 70%). Further subgroup analysis did not show a clear source of the heterogeneity, but various H<sub>2</sub>S donors exhibited positive renal protection in those studies.</p><p><strong>Conclusions: </strong>H<sub>2</sub>S could be a new approach for treating cis-AKI, while the differential efficacies among natural and slow-release H<sub>2</sub>S donors remain to be compared and evaluated further. This meta-analysis may shed light on establishing preclinical and clinical investigation guidelines for treating human cis-AKI with H<sub>2</sub>S donors.</p>\",\"PeriodicalId\":19799,\"journal\":{\"name\":\"PeerJ\",\"volume\":\"13 \",\"pages\":\"e19481\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103845/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PeerJ\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.7717/peerj.19481\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PeerJ","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.7717/peerj.19481","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景：顺铂诱导的急性肾损伤（cis-AKI）在临床上并不罕见，但预防和治疗方法有限。在动物模型中研究并确定了硫化氢（H2S）减轻顺式aki的功效。方法：根据预注册项目（PROSPERO: CRD 42023463779），检索PubMed/Medline、Embase和Web of Science数据库，检索关键词：硫化氢、顺铂、急性肾损伤和替代品。共纳入13篇符合纳入标准的文章。标准化平均差（SMD）和95%置信区间（CI）采用随机效应荟萃分析计算和汇总。结果：结果显示，H2S治疗显著改善肾功能(血清肌酐SMD = -2.96, 95% CI [-3.72 ~ -2.19], p < 0.00001；血尿素氮SMD = -2.73, 95% CI [-3.68 ~ -1.78], p < 0.00001)，降低氧化应激（超氧化物歧化酶SMD = 2.90, 95% CI [1.36 ~ 4.43], p = 0.0002）和炎症水平（白细胞介素-1β SMD = -4.41, 95% CI [-5.84 ~ -2.97], p < 0.00001）。然而，研究之间存在高度的异质性（I2 ~ 70%）。进一步的亚组分析没有显示出异质性的明确来源，但在这些研究中，各种H2S供者表现出积极的肾保护作用。结论：H2S可能是治疗顺式aki的新方法，而天然和缓释H2S供体的疗效差异仍有待进一步比较和评估。该荟萃分析可能有助于建立治疗H2S供体的人类顺性aki的临床前和临床研究指南。
Hydrogen sulfide protects against cisplatin-induced experimental nephrotoxicity in animal models: a systematic review and meta-analysis.
Background: Cisplatin-induced acute kidney injury (cis-AKI) is not rare in oncological patients clinically, but there are limited prevention and treatment methods available. The efficacy of hydrogen sulfide (H2S) in mitigating cis-AKI has been studied and determined in animal models.
Methods: According to the pre-registered program (PROSPERO: CRD 42023463779), we searched PubMed/Medline, Embase, and Web of Science databases using the keywords: hydrogen sulfide, cisplatin, acute kidney injury, and alternatives. A total of 13 articles met the inclusion criteria were included. Standardized mean difference (SMD) and 95% confidence interval (CI) were calculated and aggregated using random effects meta-analysis.
Results: The results showed that H2S treatment significantly improved renal function (serum creatinine SMD = -2.96, 95% CI [-3.72 to -2.19], p < 0.00001; blood urea nitrogen SMD = -2.73, 95% CI [-3.68 to -1.78], p < 0.00001), decreased oxidative stress (superoxide dismutase SMD = 2.90, 95% CI [1.36-4.43], p = 0.0002) and inflammation levels (interleukin-1β SMD = -4.41, 95% CI [-5.84 to -2.97], p < 0.00001). However, there was a high degree of heterogeneity between studies (I2 > 70%). Further subgroup analysis did not show a clear source of the heterogeneity, but various H2S donors exhibited positive renal protection in those studies.
Conclusions: H2S could be a new approach for treating cis-AKI, while the differential efficacies among natural and slow-release H2S donors remain to be compared and evaluated further. This meta-analysis may shed light on establishing preclinical and clinical investigation guidelines for treating human cis-AKI with H2S donors.
期刊介绍：
PeerJ is an open access peer-reviewed scientific journal covering research in the biological and medical sciences. At PeerJ, authors take out a lifetime publication plan (for as little as $99) which allows them to publish articles in the journal for free, forever. PeerJ has 5 Nobel Prize Winners on the Board; they have won several industry and media awards; and they are widely recognized as being one of the most interesting recent developments in academic publishing.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
